Lorazepam Ethanol

Oxycodone/Lorazepam/Ethanol Multiple oral doses of pregabalin were coadministered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when pregabalin was coadministered with those drugs. 

Long-acting drugs such as chlordiazepoxide and diazepam and, to a lesser extent, phenobarbital are administered in progressively decreasing doses to patients during withdrawal from physiologic dependence on ethanol or other sedative-hypnotics. Parenteral lorazepam is used to suppress the symptoms of delirium tremens. 

Treatment of ethanol withdrawal is supportive and relies on benzodiazepines, taking care to use compounds such as oxazepam and lorazepam, which are not as dependent on hepatic metabolism as most other benzodiazepines. In patients in whom monitoring is not reliable and liver function is adequate, a longer-acting benzodiazepine such as chlordiazepoxide is preferred. 

Lorazepam IV/IM 80% Propylene glycol 18% Ethanol 2% Benzyl alcohol Dilute twofold for IV injection. 

Noninterfering acetaminophen, acetylmorphine, amiodarone, amobarbital, amphetamine, bendroflumethiazide, benzocaine, benzoylecgonine, benzthiazide, butalbital, carbamaze-pine, chlorothiazide, clonazepam, cocaine, codeine, cotinine, cyclosporine, cyclothiazide, desalkylflurazepam, diamorphine, dicumerol, ephedrine, ethaciynic acid, ethanol, eth-chlorvynol, ethosuximide, furosemide, glutethimide, hydrochlorothiazide, hydrocodone, hydroflumethiazide, hydromorphone, lorazepam, mephentermine, meprobamate, meth-amphetamine, metharbital, methoxsalen, methoxyphenteramine, methsuximide, meth-ylcyclothiazide, metoprolol, MHPG, monoacetylmorphine, morphine, normethsuximide, oxazepam, oxycodone, oxymorphone, pentobarbital, phencyclidine, phenteramine, phenylephrine, phenytoin, polythiazide, primidone, prochlorperazine, salicylic acid, sulfanilamide, THC-COOH, theophylline, thiazolam, thiopental, thioridazine, tocainide, trichlo-romethiazide, trifluoperazine, valproic acid, warfarin... 

Lorazepam and its 3-0-acyl, 1-//-acyl-3-0-acyl-, and 3-0-methyl derivatives were baseline resolved on a silica column (X = 230 nm) using a 90/10 hexane/(2/l ethanol/acetonitrile) mobile phase [732], Elution was complete in <30min. The lorazepam peak was quite tailed. The retention of the enantiomers of each of these compounds was determined on six Pirkle-type chiral columns. Eluent composition ranged from 90/10 hexane/IPA to 95/5-> 91.5/8.5 hexane/(2/l ethanol/ acetonitrile) to 77/20/3 70/20/10 hexane/IPA/1,2-dichloroethane. Retention times ranged from 13.5 to 56min. Each pair was adequately resolved under one or more sets of conditions. All results are tabulated. One topic not often addressed in such studies is compound racemization half-lives. Here, neat solvents and experimental mobile phases were used. Water and neat alcohols resulted in 50% racemization in <30 min. The hexane/1,2-dichloroethane/IPA mobile phases yielded racemization times of >50 min. This time increased as the level of IPA decreased. Essentially no racemization occurred t 2 > 5000 min) in neat 1,2-dichloroethane or acetonitrile. 

---